Sinopharm vaccine reported to have 86% efficacy against Covid-19

Source : 112 Ukraine

Phase III of its clinical trials was initiated back in July
18:34, 9 December 2020

Associated Press

Sinopharm, an experimental coronavirus vaccine that was developed by China National Pharmaceutical Group, has showcased 86% efficacy. It was reported by Reuters, citing the Health Ministry of the United Arab Emirates.

It is worth noting that neither the UAE nor Sinopharm have released detailed data from their pivotal study.

UAE initiated Phase III clinical trials of this vaccine back in July. Two months later, the country authorized the emergency use of the vaccine for certain groups of the population.

"The analysis also shows 99% seroconversion rate of neutralizing antibody and 100% effectiveness in preventing moderate and severe cases of the disease," the ministry said in a statement.

Related: Pfizer warns about lack of extra vaccine shots for U.S. until summer 2021

As we reported earlier, the Russian Ministry of Health has fixed the maximum cost price of its coronavirus vaccine, Sputnik V, at 26.20 dollars (1,942 rubles) for two doses.

"Russia’s Health Ministry has registered the maximum cost price of a producer for the vaccine to prevent novel coronavirus infection - Sputnik V, which was developed by the Gamaleya National Research Center for Epidemiology and Microbiology. It is 1,942 rubles for two doses," reads the message.

Related: Sinovac vaccine effectiveness not finally proved, - Bio Farma

Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

see more